Apotex Health Plans TSX Public Listing
Apotex Health Plans Public Listing on the TSX
Canadian generic drug company Apotex Health is planning to go public by listing its shares on the Toronto Stock Exchange. The company filed a preliminary prospectus with Canadian securities regulators on Thursday.
IPO Details
The offering includes a dual treasury offering of new shares alongside a secondary offering from private equity owner SK Capital Partners and management insiders. The company has not yet disclosed the number of shares or the amount to be raised.
About Apotex
Apotex is Canada's largest pharmaceutical company by several measures, including prescriptions filled, products sold, and employees. One in every five generic prescriptions in Canada is manufactured by Apotex.
Key Products and History
Top-selling products include lenalidomide (generic Revlimid), biosimilars like Lapelga and Grastofil, and branded products Blexten and Cambia. Apotex's growth was driven by an aggressive litigation strategy challenging brand-name drug patents.
Founder Barry Sherman and his wife Honey were found dead in 2017; their murders remain unsolved.
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.
More Headlines
Tokyo Core Inflation Slows, Remains Below BOJ Target
Tokyo Core Inflation Slows, Remains Below BOJ Target
…Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
…Australian Pension Fund HUB24 Faces Regulatory Scrutiny
Australian Pension Fund HUB24 Faces Regulatory Scrutiny
…